Tenax Therapeutics (TENX) Competitors $6.41 0.00 (0.00%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$6.39 -0.02 (-0.31%) As of 09/19/2025 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TENX vs. EQ, FATE, ATOS, ZNTL, SPRO, ADAG, ANRO, HLVX, MEIP, and VTGNShould you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Equillium (EQ), Fate Therapeutics (FATE), Atossa Genetics (ATOS), Zentalis Pharmaceuticals (ZNTL), Spero Therapeutics (SPRO), Adagene (ADAG), Alto Neuroscience (ANRO), HilleVax (HLVX), MEI Pharma (MEIP), and VistaGen Therapeutics (VTGN). These companies are all part of the "pharmaceutical products" industry. Tenax Therapeutics vs. Its Competitors Equillium Fate Therapeutics Atossa Genetics Zentalis Pharmaceuticals Spero Therapeutics Adagene Alto Neuroscience HilleVax MEI Pharma VistaGen Therapeutics Tenax Therapeutics (NASDAQ:TENX) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation. Do insiders and institutionals believe in TENX or EQ? 1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 3.1% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 31.6% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, TENX or EQ? Tenax Therapeutics has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Equillium has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Is TENX or EQ more profitable? Tenax Therapeutics has a net margin of 0.00% compared to Equillium's net margin of -19.62%. Tenax Therapeutics' return on equity of -31.34% beat Equillium's return on equity.Company Net Margins Return on Equity Return on Assets Tenax TherapeuticsN/A -31.34% -30.39% Equillium -19.62%-139.56%-90.56% Does the media prefer TENX or EQ? In the previous week, Tenax Therapeutics had 1 more articles in the media than Equillium. MarketBeat recorded 3 mentions for Tenax Therapeutics and 2 mentions for Equillium. Equillium's average media sentiment score of 0.97 beat Tenax Therapeutics' score of 0.68 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Equillium 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer TENX or EQ? Tenax Therapeutics presently has a consensus price target of $18.00, indicating a potential upside of 180.81%. Equillium has a consensus price target of $1.00, indicating a potential downside of 31.51%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Tenax Therapeutics is more favorable than Equillium.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Equillium 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better valuation & earnings, TENX or EQ? Equillium has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenax TherapeuticsN/AN/A-$17.60M-$0.92-6.97Equillium$41.10M2.11-$8.07M-$0.56-2.61 SummaryTenax Therapeutics and Equillium tied by winning 8 of the 16 factors compared between the two stocks. Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENX vs. The Competition Export to ExcelMetricTenax TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.25M$3.14B$5.77B$10.45BDividend YieldN/A2.35%5.61%4.58%P/E Ratio-6.9720.9180.5026.81Price / SalesN/A262.10458.4992.96Price / CashN/A46.4637.6661.43Price / Book0.249.6015.756.39Net Income-$17.60M-$53.22M$3.30B$271.80M7 Day Performance4.91%3.11%5.35%3.51%1 Month Performance6.13%6.23%7.28%9.58%1 Year Performance79.55%11.02%80.79%28.53% Tenax Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENXTenax Therapeutics2.2895 of 5 stars$6.41flat$18.00+180.8%+79.6%$29.25MN/A-6.979EQEquillium0.8537 of 5 stars$1.71-8.6%$1.00-41.5%+71.8%$111.27M$16.55M-3.0540FATEFate Therapeutics4.0043 of 5 stars$0.96-0.8%$3.30+245.3%-75.1%$111.07M$13.63M-0.66550Positive NewsATOSAtossa Genetics1.4368 of 5 stars$0.82-2.6%$6.17+653.7%-41.9%$108.48MN/A-3.568ZNTLZentalis Pharmaceuticals1.8058 of 5 stars$1.45-2.7%$5.84+302.8%-64.0%$107.48M$67.43M-0.64160Positive NewsSPROSpero Therapeutics4.3278 of 5 stars$1.88-1.1%$5.00+166.0%+50.4%$106.92M$34.09M-1.92150Positive NewsADAGAdagene3.0801 of 5 stars$2.11-5.8%$7.00+231.8%-14.6%$105.57M$100K0.00260News CoveragePositive NewsANROAlto Neuroscience2.4126 of 5 stars$3.76-3.5%$8.50+126.4%-73.5%$105.33MN/A-1.57N/ATrending NewsHLVXHilleVax1.4623 of 5 stars$2.10+0.5%$2.00-4.8%N/A$104.79MN/A-1.4720News CoverageAnalyst UpgradeShort Interest ↑MEIPMEI Pharma0.7141 of 5 stars$3.19+14.7%N/A+7.0%$104.72MN/A-0.67100Gap UpHigh Trading VolumeVTGNVistaGen Therapeutics1.2002 of 5 stars$3.25-4.1%N/A-5.4%$104.01M$490K-1.8340 Related Companies and Tools Related Companies Equillium Alternatives Fate Therapeutics Alternatives Atossa Genetics Alternatives Zentalis Pharmaceuticals Alternatives Spero Therapeutics Alternatives Adagene Alternatives Alto Neuroscience Alternatives HilleVax Alternatives MEI Pharma Alternatives VistaGen Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENX) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TENX Stock Alerts